SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy
SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy
Simple item page
Full item details
- dc.contributor.author
- Cheung, Peter K.
- Lapointe, Hope R.
- Sang, Yurou
- Ennis, Siobhan
- Mwimanzi, Francis
- Speckmaier, Sarah
- Barad, Evan
- Dong, Winnie
- Liang, Richard
- Simons, Janet
- Lowe, Christopher F.
- Romney, Marc G.
- Brumme, Chanson J.
- Niikura, Masahirob
- Brockman, Mark A.
- Brumme, Zabrina L.
- COVID-19 vaccine immunity study team
- dc.date.accessioned
- 2024-11-22T16:44:43Z
- dc.date.available
- 2024-11-22T16:44:43Z
- dc.date.issued
- 2023-04-01
- dc.description.abstract - en
- OBJECTIVE: Limited data exist regarding the immune benefits of fourth COVID-19 vaccine doses in people with HIV (PWH) receiving antiretroviral therapy (ART), particularly now that most have experienced a SARS-CoV-2 infection. We quantified wild-type, Omicron-BA.5 and Omicron-BQ.1-specific neutralization up to 1 month post-fourth COVID-19 vaccine dose in 63 (19 SARS-CoV-2-naive and 44 SARS-CoV-2-experienced) PWH. DESIGN: A longitudinal observational cohort. METHODS: Quantification of wild-type-, Omicron-BA.5, and Omicron-BQ.1-specific neutralization using live virus assays. RESULTS: Participants received monovalent (44%) and bivalent (56%) mRNA fourth doses. In COVID-19-naive PWH, fourth doses enhanced wild-type and Omicron-BA.5-specific neutralization modestly above three-dose levels (P = 0.1). In COVID-19-experienced PWH, fourth doses enhanced wild-type specific neutralization modestly (P = 0.1) and BA.5-specific neutralization substantially (P = 0.002). Consistent with humoral benefits of ’hybrid’ immunity, COVID-19-experienced PWH exhibited the highest neutralization post-fourth dose, wherein those with Omicron-era infections displayed higher wild-type specific (P = 0.04) but similar BA.5 and BQ.1-specific neutralization than those with pre-Omicron-era infections. Nevertheless, BA.5-specific neutralization was significantly below wild-type in everyone regardless of COVID-19 experience, with BQ.1-specific neutralization lower still (both P < 0.0001). In multivariable analyses, fourth dose valency did not affect neutralization magnitude. Rather, an mRNA-1273 fourth dose (versus a BNT162b2 one) was the strongest correlate of wild-type specific neutralization, while prior COVID-19, regardless of pandemic era, was the strongest correlate of BA.5 and BQ.1-specific neutralization post-fourth dose. CONCLUSION: Fourth COVID-19 vaccine doses, irrespective of valency, benefit PWH regardless of prior SARS-CoV-2 infection. Results support recommendations that all adults receive a fourth COVID-19 vaccine dose within 6 months of their third dose (or their most recent SARS-CoV-2 infection).
- dc.description.sponsorship
- This work was supported by funding from Genome BC, Michael Smith Health Research BC and the BCCDC Foundation for Public Health through a rapid SARS-CoV-2 vaccine research initiative in BC award (VAC-009 to Z.L.B., M.A.B.). It was also supported by the Public Health Agency of Canada (PHAC) through a COVID-19 Immunology Task Force (CITF) COVID-19 Award (2020-HQ-000120 to Z.L.B., M.G.R., M.A.B.). Additional funding was received from the Canadian Institutes for Health Research (GA2–177713; to M.A.B.), the Coronavirus Variants Rapid Response Network (FRN-175622; to M.A.B.), the Canada Foundation for Innovation through two Exceptional Opportunities Fund COVID-19 awards (the first to C.J.B. and C.F.L., and the second to M.N., M.A.B., Z.L.B.), a British Columbia Ministry of Health–Providence Healthcare Research Institute COVID-19 Research Priorities Grant (to C.J.B. and C.F.L.). FM is supported by a fellowship from the CIHR Canadian HIV Trials Network. E.B. was supported by an SFU Undergraduate Research Award. Z.L.B. holds a Scholar Award from Michael Smith Health Research BC.
- dc.identifier.doi
- https://doi.org/10.1097/QAD.0000000000003519
- dc.identifier.issn
- 1473-5571
- dc.identifier.pubmedID
- 36789806
- dc.identifier.uri
- https://open-science.canada.ca/handle/123456789/3173
- dc.language.iso
- en
- dc.publisher - en
- Wolters Kluwer Health, Inc.
- dc.rights - en
- Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
- dc.rights - fr
- Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
- dc.rights.uri - en
- https://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.rights.uri - fr
- https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
- dc.subject - en
- Health
- Coronavirus diseases
- dc.subject - fr
- Santé
- Maladie à coronavirus
- dc.subject.en - en
- Health
- Coronavirus diseases
- dc.subject.fr - fr
- Santé
- Maladie à coronavirus
- dc.title - en
- SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy
- dc.type - en
- Article
- dc.type - fr
- Article
- local.article.journalissue
- 5
- local.article.journaltitle - en
- AIDS
- local.article.journalvolume
- 37
- local.pagination
- F11-F18
- local.peerreview - en
- Yes
- local.peerreview - fr
- Oui
Download(s)
Original bundle
1 - 1 of 1
Name: cheung-covid-19-vaccine-people-with-hiv.pdf
Size: 1.22 MB
Format: PDF
Collection(s)